The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
898
June 11, 1993
View Complete Issue         Table of Contents 2019 
Recombinant Antihemophilic Factor
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Recombinant Antihemophilic Factor
June 11, 1993 (Issue: 898)
Recombinate (Baxter) and Kogenate (Miles), two recombinant-DNA-derived Factor VIII (rFVIII) preparations, were recently approved for marketing by the US Food and Drug Administration. Clotting factor concentrates are generally prepared from large ...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Recombinant Antihemophilic Factor
Article code: 898a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.